The Latest Cardiac and Vascular News
Artivion to Host Investor & Analyst Day on March 23, 2022 ATLANTA, Jan. 18, 2022 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words “aorta”, “innovation”, and […]
ATLANTA, Nov. 4, 2021 /PRNewswire/ — Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in […]
ATLANTA, Sept. 22, 2021 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony “Tony” Semedo to its Board of Directors effective October 1, 2021. “We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors,” […]
ATLANTA, July 29, 2021 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc. (“Baxter”) (NYSE: BAX ), for up to $60.8 million in cash. Of the $60.8 million, CryoLife will receive […]
ATLANTA, April 29, 2021 /PRNewswire/ — First Quarter and Recent Business Highlights: Achieved total revenues of $71.1 million in the first quarter 2021 versus $66.4 million in the first quarter of 2020, an increase of 7% on a GAAP basis and 3% on a non-GAAP proforma constant currency basis Net loss was ($3.1) million, or ($0.08) per share, in […]
ATLANTA, Feb. 11, 2021 /PRNewswire/ — Fourth Quarter and Recent Business Highlights: Achieved total revenues of $67.9 million in the fourth quarter 2020 versus $69.7 million in the fourth quarter of 2019 Total revenues decreased 3% on a GAAP basis and 5% on a non-GAAP proforma constant currency basis versus fourth quarter 2019 Excluding TMR, fourth […]
ATLANTA, July 30, 2020 /PRNewswire/ — Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 2019– Total revenues decreased 24% and decreased 23% on a non-GAAP constant currency basis versus second quarter 2019 Completed $100.0 million convertible debt financing for general corporate […]
ATLANTA, June 19, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY) (“CryoLife” or “the Company”), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under […]
ATLANTA, June 18, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY) (“CryoLife” or “the Company”), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends to offer, subject to market conditions and other factors, $100,000,000 aggregate principal amount of convertible senior notes due 2025 (the “Notes”) in a private placement to qualified […]
Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA, May 7, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if […]
